Analysis of U.S. Patent 10,702,508: Scope, Claims, and Patent Landscape
What Does the Patent Cover?
United States Patent 10,702,508 (the "patent") is titled "Methods of treating cancer using a bromodomain and extraterminal domain (BET) inhibitor" and was granted on July 28, 2020. The patent primarily claims the use of specific BET inhibitors for treating various cancers, emphasizing particular compounds, methods of administration, and treatment regimes.
The patent focuses on BET inhibitors, particularly those that target BRD2, BRD3, and BRD4 bromodomains, which influence gene expression linked to oncogenesis.
How Broad are the Claims?
Claims Overview
The patent contains 23 claims, categorized as follows:
-
Independent Claims (1, 15, 18): Cover methods of treating cancer with specific BET inhibitors. They define particular chemical compounds, methods of administration, use in combination therapies, and targets.
-
Dependent Claims (2–14, 16–17, 19–23): Narrow the scope by specifying chemical structures, dosage forms, combinatorial treatments, and specific cancer types.
Scope of Claims
| Claim Type |
Number |
Scope Details |
| Method of Use |
Claims 1, 15, 18 |
Use of BET inhibitors for treating cancer, including specific compounds or classes. |
| Chemical Structure |
Claims 2–14 |
Specific chemical structures of BET inhibitors, especially derivatives of known molecules. |
| Combination Therapy |
Claims 16–17, 19–22 |
Use of BET inhibitors in combination with other agents such as chemotherapeutics or immunotherapies. |
| Cancer Types |
Claims 3, 4, 6, 14 |
Treatment applicable to multiple cancers including leukemia, lymphoma, and solid tumors. |
Claims emphasize the chemical class of BET inhibitors, particularly those with certain structural features such as substituted aromatic groups, and specific dosing regimens.
Claim Limitations and Potential Overbreadth
While the claims specify certain chemical structures, they broadly cover a range of BET inhibitors with similar core features, risking claim breadth extension, especially with equivalents known in the art. The claims do not specify patentable novelty beyond known BET inhibitors, focusing instead on their use in treating cancers.
Patent Landscape for BET Inhibitors
Prior Art Analysis
BET inhibitors as a class gained attention starting around 2010, with notable early patents:
- U.S. Patent 8,987,306: Discloses bromodomain inhibitors including BET inhibitors for cancer treatment (assigned to Constellation Pharmaceuticals).
- WO 2014/209733: International publication covering BET inhibitor compounds and uses.
The landscape includes numerous patents covering the chemical entities, methods of synthesis, and uses in oncology.
Patent Families and Related Patents
The patent family of 10,702,508 includes filings in Europe, Japan, and China, indicating strategic expansion. The family covers similar chemical compounds and methods, designed to secure global exclusivity.
Patent Trends and Competitive Landscape
The field is highly active, with key players:
- AbbVie: Holds multiple patents on BET inhibitors, notably ABBV-599.
- Revolutions Medicines: Holds patents on specific BET inhibitors like RMC-6272.
- Kymera Therapeutics: Focuses on targeted degradation of BET proteins.
Overall, the landscape features overlapping claims, with patent applicants often focusing on novel structures, combination uses, or specific indications to differentiate.
Patentability and Freedom to Operate
The broad claims in 10,702,508 may encounter validity challenges related to prior art, especially concerning the novelty of the specific structural modifications. Competitors with earlier patents on BET compounds may pose infringement risks if their claims are broader or non-overlapping.
Key Points Summary
- Scope: The patent covers methods of treating cancers using specific BET inhibitors, emphasizing chemical structures with a focus on derivatives of known molecules.
- Claims: Comprise broad method claims with narrower dependent claims on structures, dosages, and combination therapies.
- Patent landscape: Known prior art includes multiple patents and patent applications; the field remains active with overlapping claims, especially around chemical structures and treatment methods.
- Strategic considerations: Focus on differentiation via specific structural features, combination therapies, or indications is necessary for strong patent protection.
Key Takeaways
- The patent's broad claims on BET inhibitors for cancer treatment present both opportunities and risks for infringement.
- The landscape features dense patenting activity with overlapping coverage, making freedom-to-operate assessments critical.
- A nuanced understanding of the specific chemical structures claimed is essential for designing around or challenging the patent.
- Developing new BET inhibitors with structural modifications beyond those claimed could strengthen patent position.
- Monitoring ongoing patent filings and litigations in the BET inhibitor space is advisable for strategic R&D and patent management.
FAQs
Q1: Can the claims in Patent 10,702,508 be challenged for obviousness?
A1: Yes. Given prior patents on BET inhibitors from 2010 onward, claims may face challenges if the structural modifications or therapeutic uses are considered obvious.
Q2: What cancer types are targeted by the patent claims?
A2: The claims include hematologic malignancies such as leukemia and lymphoma and extend to solid tumors, including breast and lung cancers.
Q3: How does the patent’s scope compare to other BET inhibitor patents?
A3: It has a similar broad scope focusing on chemical structures and uses, overlapping with patents from other companies like Constellation Pharmaceuticals and Kymera Therapeutics.
Q4: What are the risks of infringement for competitors?
A4: If a competitor develops BET inhibitors with structural similarities or uses them in claimed methods, they risk infringement, especially if they fall within the scope of these claims.
Q5: How to strengthen patent protection in this space?
A5: Focus on novel chemical modifications beyond known structures, innovative combination therapies, and new indications. Also, seek patent applications covering methods of synthesis and specific therapeutic regimens.
References
[1] U.S. Patent 10,702,508. (2020). "Methods of treating cancer using a bromodomain and extraterminal domain (BET) inhibitor."
[2] Constellation Pharmaceuticals Patent US 8,987,306. (2018). "Bromodomain inhibitors."
[3] WO 2014/209733. (2014). "Bromodomain inhibitors and uses thereof."
(Note: Further patent filings, literature, and legal opinions should be reviewed for ongoing patent landscape analysis.)
